Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Swiss Exchange  >  Novartis    NOVN   CH0012005267

NOVARTIS

(NOVN)
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Novartis : Sandoz generics unit buying Aspen's Japanese operations

share with twitter share with LinkedIn share with facebook
share via e-mail
0
11/11/2019 | 01:19am EST

Novartis Sandoz generic drug unit is buying Aspen's Japanese operations for an initial payment of 300 million euros ($330.60 million) to expand in the world's third-biggest generic medicines market, the Swiss drugmaker said on Monday.

Sandoz has also agreed, upon certain conditions being fulfilled after closing, to pay deferred consideration not expected to exceed 100 million euros, the company said in a statement.

(Reporting by John Miller; editing by Thomas Seythal)

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on NOVARTIS
12/05EUROPE : European shares dip, Glencore slides to three-year low
RE
12/05TODAY'S COMPANIES NEWS : Amazon, Huawei, Moncler, Fiat Chrysler…
12/05NOVARTIS : Expects to Sustain Long-Term Growth With Pipeline of Potential Blockb..
DJ
12/05NOVARTIS : CHF0.50(REGD) Novartis Tender Offer For The Medicines Company Commenc..
DJ
12/03NOVARTIS : breadth of data at 2019 ASH demonstrates commitment to reimagining me..
AQ
11/30Novartis Aims to Ace Tough Market -- WSJ
DJ
11/29NEWS HIGHLIGHTS : Top Company News of the Day
DJ
11/29NEWS HIGHLIGHTS : Top Company News of the Day
DJ
11/29NEWS HIGHLIGHTS : Top Company News of the Day
DJ
11/29Health Care Down As Traders Hedge On Outcome Of M&A Activity -- Health Care R..
DJ
More news
Financials (USD)
Sales 2019 47 771 M
EBIT 2019 14 144 M
Net income 2019 9 247 M
Debt 2019 17 154 M
Yield 2019 3,21%
P/E ratio 2019 21,4x
P/E ratio 2020 21,5x
EV / Sales2019 4,72x
EV / Sales2020 4,47x
Capitalization 209 B
Chart NOVARTIS
Duration : Period :
Novartis Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends NOVARTIS
Short TermMid-TermLong Term
TrendsBullishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 25
Average target price 97,60  $
Last Close Price 92,09  $
Spread / Highest target 29,3%
Spread / Average Target 5,98%
Spread / Lowest Target -12,8%
EPS Revisions
Managers
NameTitle
Vasant Narasimhan Chief Executive Officer
Hans Jörg Reinhardt Independent Non-Executive Chairman
Harry Werner Kirsch Chief Financial Officer
John Tsai Chief Medical Officer
Elizabeth Theophille Chief Technology & Digital Officer
Sector and Competitors
1st jan.Capitalization (M$)
NOVARTIS21.74%207 450
JOHNSON & JOHNSON8.14%367 304
ROCHE HOLDING AG25.10%263 429
MERCK AND COMPANY16.15%225 956
PFIZER-12.88%210 463
BRISTOL-MYERS SQUIBB COMPANY13.31%139 432